Genenta will meet Institutional Investors at the 10th Annual LifeSci Advisors Corporate Access Event from January 6th to 14th.
The Event will host on Friday Jan 8 at 10AM EST a gene-therapy panel with prof. Luigi Naldini as the lynch-pin.

Register here >

Healthcare: Italy on the Move 2021, on Jan 13th, 2021, at 8:00 am PST. John Carroll, editor-in-chief of Endpoints News, will moderate as the CEO’s of top Italian Biotech. Featured presenters at this year’s event include Genenta among other stand-out firms.

Read more >

Cancer ImmunoGeneTherapy

Temferon™: Tumor Immunotherapy by Autologous Hematopoietic-Stem-Cell Gene Transfer

We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug.

Genenta is assessing Temferon in a Phase I/II trial with newly diagnosed Glioblastoma Multiforme patients

Luigi Naldini, Winner of the 2019 Jeantet-Collen Prize for Translational Medicine

About Us

Genenta Science is a company developing a new generation of gene therapies based on transcriptional and mirRNA-mediated control.

LEARN MORE

Our Science

Using gene vectors, microRNA targets sequences and transgenes for preventing or reducing expression of the transgenes.

LEARN MORE

Our Pipeline

Genenta Science is leveraging its Temferon™ technology platform to treat cancers using a novel immuno-gene therapy approach

LEARN MORE

News

March, 2015. Genenta Science banked an overall USD 11.0 million Series A round.

LEARN MORE

Cell & Gene Therapy Insights

Cellular Immuno-Oncology 4.0

Interview

The promise of tumor-targeted gene-based delivery of immune-activating cytokines

LUIGI NALDINI is the Director of the San Raffaele Telethon Institute for Gene Therapy and Professor at the San Raffaele University and Milan, Italy. He has pioneered the development and applications of lentiviral vectors for gene therapy and contributed to advance targeted genome editing in cell and gene therapy. He is member of EMBO, past President of ESGCT, and received the Outstanding Achievement Award from ASGCT in 2014 and from ESGCT in 2015, the Beutler Prize from ASH in 2017 and the 2019 Jeantet-Collen Prize for Translational Medicine.